Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Receivables (2016 - 2025)

Historic Receivables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $8.5 million.

  • Enanta Pharmaceuticals' Receivables rose 1004.15% to $8.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.5 million, marking a year-over-year increase of 1004.15%. This contributed to the annual value of $6.9 million for FY2025, which is 355.1% up from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Receivables is $8.5 million, which was up 1004.15% from $6.9 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Receivables ranged from a high of $27.6 million in Q4 2021 and a low of $6.6 million during Q3 2024
  • For the 5-year period, Enanta Pharmaceuticals' Receivables averaged around $14.4 million, with its median value being $13.2 million (2023).
  • In the last 5 years, Enanta Pharmaceuticals' Receivables surged by 1592.77% in 2021 and then plummeted by 6381.23% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Receivables (Quarter) stood at $27.6 million in 2021, then decreased by 18.31% to $22.6 million in 2022, then plummeted by 63.81% to $8.2 million in 2023, then fell by 5.57% to $7.7 million in 2024, then rose by 10.04% to $8.5 million in 2025.
  • Its Receivables stands at $8.5 million for Q4 2025, versus $6.9 million for Q3 2025 and $8.3 million for Q2 2025.